

October 2017

A comprehensive medicinal chemistry study of imipridone antitumor agents developed in collaboration with Oncoceutics and El-Deiry research group at Penn State Hershey and Fox Chase Cancer Center was published in *Cell Cycle*.

Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. *Cell Cycle*. 2017 Oct 2;16(19):1790-1799. doi: 10.1080/15384101.2017.1325046.